Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years

This article was originally published here

Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2% (95% confidence

The post Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply